<DOC>
	<DOCNO>NCT00538694</DOCNO>
	<brief_summary>To evaluate safety efficacy daptomycin adult pneumonia due Streptococcus pneumoniae .</brief_summary>
	<brief_title>Comparative Study Cidecin™ ( Daptomycin ) Rocephin® ( Ceftriaxone ) Treatment Moderate Severe Community-Acquired Acute Bacterial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>1 . Provide sign date informed consent . 2 . Adults , 18 year age old either gender race . Female patient childbearing potential MUST nonpregnant ( confirm negative serum pregnancy test ) , nonlactating , must willing practice reliable birth control measure least 28 day treatment study drug ( ) . 3 . Must exhibit clinical signs/symptoms radiographic appearance pneumonia : presence new pulmonary infiltrate chest radiograph ; fever ( oral &gt; 38.0 degree C/100.4 degree F ) ; least one follow sign symptom consistent diagnosis acute bacterial pneumonia : acute onset , chill , chest pain/dyspnea , cough , sputum production . 4 . Pneumonia : require hospitalization ; require IV antibiotic therapy ; anticipate &gt; =5 day IV therapy ; ( Grade II ) O2 saturation &lt; 90 % PaO2 &lt; 60 mmHg room air . 5 . Provide suitable sputum specimen Gram'sstain culture . If expectorate sputum transtracheal aspirate : &gt; 10 lancetshaped Grampositive diplococci/oilimmersion field ( 1000x ) ; &lt; 10 squamous epithelial cells/lowpower field ( 100x ) ; &gt; 25 leukocytes/lowpower field ( 100x ) . 6 . An elevated total peripheral white blood cell count ( WBC &gt; 10,000/mm3 ) ; &gt; 15 % immature neutrophil ( band ) , regardless total peripheral white count ; leukopenia total WBC &lt; 4500/mm3 . 7 . Willingness participate study complete followup assessment . 1 . Grade I pneumonia risk classification , Grade II O2 saturation &gt; 90 % room air and/or PaO2 &gt; 60 mmHg room air ( base Fine Score ; Attachment 8 ) . 2 . Patients Grade V pneumonia ( base Fine Score ; Attachment 8 ) . 3 . Respiratory failure without mechanical ventilatory support ( i.e. , PaO2 / FiO2 &lt; 200 ) , underlie lung disease preclude interpretation study result ( e.g. , cystic fibrosis , lung cancer ) . 4 . Loculated empyema . 5 . Severe shock ( systolic blood pressure &lt; 90 mm Hg &gt; 30 minute correct fluid bolus ) . 6 . Clinical evidence bacterial meningitis ( base lumbar puncture result ) . 7 . Renal impairment ( calculated creatinine clearance &lt; 30 mL/min ) ; hepatic dysfunction ( ALT/AST 3 time upper limit normal bilirubin &gt; =2.0 mg/dL ) ; clinical histologic diagnosis cirrhosis another form chronic liver disease , chronic active hepatitis . 8 . Moribund clinical condition : high likelihood death first 48 hour . 9 . Patients severely immunocompromised due underlie disease exogenous therapy , CD4 count &lt; 100/mm3 . 10 . Inability tolerate ceftriaxone history allergy betalactam antibiotic ( history rash alone exclude patient ) . 11 . Any individual previously treat potentially effective antiinfective agent &gt; =24 hour immediately prior enrollment , prior treatment investigational drug ( include experimental biologic agent ) previous 30 day prior therapy daptomycin . 12 . Patients must continue HMGCoA reductase inhibitor therapy ( e.g. , simvastatin , lovastatin , etc ) study treatment period . 13 . Use &gt; 0.5 mg/kg/day prednisone equivalent &gt; 1 week precede enrollment . 14 . Anticipation second systemic antibiotic require . 15 . Induction chemotherapy within 2 week prior enrollment ( exogenous therapy anticipate result PMN count &lt; 200 mm3 Treatment Phase ) , patient severe neutropenia ( &lt; 200 PMN cells/mm3 ) . 16 . Patients consider unreliable return visit comply study procedure . 17 . Functionally surgically asplenic ( e.g. , sickle cell disease , multiple myeloma ) . 18 . Neoplastic disease , except basal cell squamous cell cancer skin active time enrollment within 1 year prior enrollment . 19 . Women pregnant nursing/lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Moderate severe community-acquired acute bacterial pneumonia due S. Pneumoniae</keyword>
</DOC>